JP2009524697A5 - - Google Patents

Download PDF

Info

Publication number
JP2009524697A5
JP2009524697A5 JP2008552611A JP2008552611A JP2009524697A5 JP 2009524697 A5 JP2009524697 A5 JP 2009524697A5 JP 2008552611 A JP2008552611 A JP 2008552611A JP 2008552611 A JP2008552611 A JP 2008552611A JP 2009524697 A5 JP2009524697 A5 JP 2009524697A5
Authority
JP
Japan
Prior art keywords
fumaric acid
containing cores
acid
except
instead
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008552611A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009524697A (ja
JP5433236B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/061217 external-priority patent/WO2007090082A2/en
Publication of JP2009524697A publication Critical patent/JP2009524697A/ja
Publication of JP2009524697A5 publication Critical patent/JP2009524697A5/ja
Application granted granted Critical
Publication of JP5433236B2 publication Critical patent/JP5433236B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2008552611A 2006-01-27 2007-01-29 弱塩基性選択性セロトニン５−ｈｔ３遮断剤および有機酸を含む薬物送達系 Expired - Fee Related JP5433236B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76275006P 2006-01-27 2006-01-27
US60/762,750 2006-01-27
PCT/US2007/061217 WO2007090082A2 (en) 2006-01-27 2007-01-29 Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013165542A Division JP5918179B2 (ja) 2006-01-27 2013-08-08 弱塩基性選択性セロトニン５−ｈｔ３遮断剤および有機酸を含む薬物送達系

Publications (3)

Publication Number Publication Date
JP2009524697A JP2009524697A (ja) 2009-07-02
JP2009524697A5 true JP2009524697A5 (OSRAM) 2010-03-25
JP5433236B2 JP5433236B2 (ja) 2014-03-05

Family

ID=38325269

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008552611A Expired - Fee Related JP5433236B2 (ja) 2006-01-27 2007-01-29 弱塩基性選択性セロトニン５−ｈｔ３遮断剤および有機酸を含む薬物送達系
JP2013165542A Expired - Fee Related JP5918179B2 (ja) 2006-01-27 2013-08-08 弱塩基性選択性セロトニン５−ｈｔ３遮断剤および有機酸を含む薬物送達系
JP2015188001A Withdrawn JP2016014048A (ja) 2006-01-27 2015-09-25 弱塩基性選択性セロトニン５−ｈｔ３遮断剤および有機酸を含む薬物送達系

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013165542A Expired - Fee Related JP5918179B2 (ja) 2006-01-27 2013-08-08 弱塩基性選択性セロトニン５−ｈｔ３遮断剤および有機酸を含む薬物送達系
JP2015188001A Withdrawn JP2016014048A (ja) 2006-01-27 2015-09-25 弱塩基性選択性セロトニン５−ｈｔ３遮断剤および有機酸を含む薬物送達系

Country Status (14)

Country Link
US (1) US20070190145A1 (OSRAM)
EP (2) EP1976491B1 (OSRAM)
JP (3) JP5433236B2 (OSRAM)
KR (1) KR101413613B1 (OSRAM)
CN (2) CN103211779B (OSRAM)
AU (1) AU2007211091B8 (OSRAM)
BR (1) BRPI0707324A2 (OSRAM)
CA (1) CA2640460C (OSRAM)
ES (2) ES2550035T3 (OSRAM)
IL (1) IL193020A0 (OSRAM)
NZ (1) NZ570039A (OSRAM)
RU (1) RU2490012C2 (OSRAM)
WO (1) WO2007090082A2 (OSRAM)
ZA (1) ZA200806497B (OSRAM)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140088230A (ko) * 2006-01-27 2014-07-09 앱탈리스 파마테크, 인코포레이티드 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템
EP2187873B1 (en) * 2007-08-13 2018-07-25 Abuse Deterrent Pharmaceutical Llc Abuse resistant drugs, method of use and method of making
WO2009076361A1 (en) * 2007-12-10 2009-06-18 Eurand, Inc. Orally disintegrating tablets comprising diphenhydramine
US20090169620A1 (en) * 2007-12-21 2009-07-02 Venkatesh Gopi M Orally disintegrating tablet compositions of temazepam
CN101910113A (zh) * 2007-12-28 2010-12-08 怡百克制药公司 左旋多巴控释制剂及其用途
EP2090297A1 (en) * 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
TWI519322B (zh) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
WO2010026993A1 (ja) * 2008-09-03 2010-03-11 武田薬品工業株式会社 製剤における吸収性改善方法および吸収性が改善された製剤
WO2010096814A1 (en) * 2009-02-23 2010-08-26 Eurand, Inc. Controlled-release compositions comprising a proton pump inhibitor
CA2757979A1 (en) * 2009-04-09 2010-10-14 Alkermes Pharma Ireland Limited Controlled-release clozapine compositions
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
EP2506714A4 (en) * 2009-11-30 2013-07-03 Aptalis Pharmatech Inc MOUTH ONDANSETRON TABLET COMPOSITIONS TO PREVENT EVIL AND CRUSH
JP5854476B2 (ja) 2009-11-30 2016-02-09 アデア ファーマスーティカルズ，インコーポレイテッド 圧縮性コーティングで被覆された医薬組成物及び錠剤並びに製造方法
KR101143997B1 (ko) * 2010-03-04 2012-05-09 한미사이언스 주식회사 유산균 제제 및 5-ｈｔ4 수용체 효능제를 함유하는 경구 투여용 복합 제제 및 이의 제조방법
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
US9011912B2 (en) 2010-10-07 2015-04-21 Abon Pharmaceuticals, Llc Extended-release oral dosage forms for poorly soluble amine drugs
ES2813859T3 (es) 2010-12-02 2021-03-25 Adare Pharmaceuticals Inc Gránulos de dispersión rápida, comprimidos de desintegración oral y métodos
ES2823000T3 (es) 2013-10-07 2021-05-05 Impax Laboratories Llc Formulaciones muco-adhesivas de liberación controlada de levodopa y/o ésteres de levodopa y usos de las mismas
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
MX2016007786A (es) * 2013-12-16 2017-03-03 Massachusetts Inst Technology Formulaciones de sal de micronutrientes fortificadas.
JP6461186B2 (ja) 2014-03-11 2019-01-30 レッド ヒル バイオファーマ リミテッドＲｅｄＨｉｌｌ Ｂｉｏｐｈａｒｍａ Ｌｔｄ． 悪心、嘔吐または下痢の症状を処置するためのオンダンセトロン徐放固形製剤
WO2016053091A1 (en) * 2014-10-01 2016-04-07 Oxytone Bioscience B.V. Orally disintegrating solid pharmaceutical dosage unit containing a partus control substance
ES2690140T3 (es) * 2014-10-01 2018-11-19 Oxytone Bioscience B.V. Unidad de dosificación farmacéutica sólida de desintegración oral que contiene una sustancia de control del parto
CN104473895A (zh) * 2014-11-20 2015-04-01 美吉斯制药（厦门）有限公司 拉莫三嗪口腔崩解缓释片
US10406336B2 (en) * 2016-08-03 2019-09-10 Neil S. Davey Adjustable rate drug delivery implantable device
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
CN108624005B (zh) * 2017-03-24 2021-10-29 华东理工大学 基于poc和介孔纳米微球的双因子缓释系统
AU2021292406B2 (en) 2020-06-18 2024-03-14 XWPharma Ltd. Controlled release granulations of water-soluble active pharmaceutical ingredients
CN116261451A (zh) 2020-07-24 2023-06-13 凯瑞康宁生物工程有限公司 γ-羟基丁酸衍生物的药物组合物和药物动力学
CN115666527B (zh) 2020-10-05 2025-03-07 凯瑞康宁生物工程有限公司 γ-羟基丁酸衍生物的修饰释放组合物
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
JP2024501235A (ja) 2020-12-22 2024-01-11 アムニール ファーマスーティカルズ エルエルシー レボドパ投薬レジメン
TW202300139A (zh) 2021-03-19 2023-01-01 凱瑞康寧生技股份有限公司 γ-羟基丁酸衍生物的聯合釋放製劑的藥代動力學
WO2022233885A2 (en) * 2021-05-03 2022-11-10 Cambridge Glycoscience Ltd Soluble and insoluble saccharide compositions and related methods
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3634584A (en) * 1969-02-13 1972-01-11 American Home Prod Sustained action dosage form
US3954959A (en) * 1973-03-28 1976-05-04 A/S Alfred Benzon Oral drug preparations
GB1468172A (en) * 1973-03-28 1977-03-23 Benzon As Alfred Oral drug preparations
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
CH647676A5 (fr) * 1978-12-22 1985-02-15 Donald E Panoz Formes galeniques a usage oral, a liberation programmee et leurs procedes de preparation.
US4381546A (en) * 1979-03-02 1983-04-26 Paradyne Corporation System for the quantitative measurement of impairments in the communication channel of a quadrature amplitude modulation data communication system
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3124090A1 (de) * 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
US4894240A (en) * 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
EP0225085A1 (en) * 1985-11-13 1987-06-10 ELAN CORPORATION, Plc Controlled absorption pharmaceutical formulation
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
IE58401B1 (en) * 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
DE3627423A1 (de) * 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
AU2016992A (en) * 1991-05-20 1992-12-30 Marion Laboratories, Inc. Multi-layered controlled release formulation
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
JPH0710745A (ja) * 1993-06-22 1995-01-13 Tanabe Seiyaku Co Ltd 放出開始時間制御型腸デリバリー経口製剤
JPH08157392A (ja) * 1994-12-01 1996-06-18 Kanegafuchi Chem Ind Co Ltd 放出制御型製剤
SI9500173B (sl) * 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
DE69901938T3 (de) * 1998-03-06 2012-08-02 Aptalis Pharma S.R.L. Schnell zerfallende tablette
US6602521B1 (en) * 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
HU230454B1 (hu) * 1998-11-02 2016-07-28 Alkermes Pharma Ireland Limited Metilfenidátot tartalmazó módosított felszabadulású sokszemcsés készítmény
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6936275B2 (en) * 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
JP2004508278A (ja) * 2000-01-20 2004-03-18 デルシス　ファーマシューティカル　コーポレイション 多段薬物投与形態
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
YU32003A (sh) * 2000-10-30 2006-05-25 Teva Pharmaceutical Industries Ltd. Novi kristalni i solvatni oblici ondansteron hlorovodonika i postupci za njihovo pripremanje
WO2003000169A1 (fr) * 2001-06-20 2003-01-03 Takeda Chemical Industries, Ltd. Procede de fabrication de comprimes
US6500454B1 (en) * 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US20040019096A1 (en) * 2001-10-23 2004-01-29 Vlassios Andronis Novel formulations of carvedilol
US6663888B2 (en) * 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
MY139719A (en) * 2002-02-12 2009-10-30 Glaxo Group Ltd Oral dosage form for controlled drug release
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
US20040265375A1 (en) * 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
WO2004096182A1 (en) * 2003-04-30 2004-11-11 Ranbaxy Laboratories Limited Extended release matrix tablets of carvedilol
DE10353186A1 (de) * 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz
WO2005077341A1 (en) * 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Orally disintegrating pharmaceutical compositions of ondansetron
US8545881B2 (en) * 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
US9050249B2 (en) * 2004-04-30 2015-06-09 Astellas Pharma Inc. Oral pharmaceutical compositions in timed-release particle form and fast-disintegrating tablets containing this composition
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ589750A (en) 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
US20060280795A1 (en) * 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
CA2635313C (en) * 2005-12-29 2013-12-31 Osmotica Corp. Triple combination release multi-layered tablet
NZ576237A (en) * 2006-10-24 2011-12-22 Helsinn Healthcare Sa Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids

Similar Documents

Publication Publication Date Title
JP2009524697A5 (OSRAM)
LTC3170818I2 (lt) Kietos 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties formos
JP2011508438A5 (OSRAM)
JP2008501714A5 (OSRAM)
JP2012065100A5 (OSRAM)
EP2367808A4 (en) PROGESTATIVE 3- (6,6-ETHYLENE-17b-HYDROXY-3-OXO-17a-PREGNA-4-EN-17a-YL) PROPIONIC ACID g-LACTONE
JP2010514554A5 (OSRAM)
JP2012502876A5 (OSRAM)
JP2010195825A5 (OSRAM)
JP2011526809A5 (OSRAM)
JP2013507321A5 (OSRAM)
JP2008520565A5 (OSRAM)
JP2010518805A5 (OSRAM)
IL195179A0 (en) Phenylamino-benzoxazole substituted carboxylic acids, method for their production and use thereof as medicaments
JP2014047406A5 (OSRAM)
JP2014530840A5 (OSRAM)
JP2013507408A5 (OSRAM)
WO2010151095A8 (en) Novel acetylsalicylic acid salts
JP2013500200A5 (OSRAM)
JP2011525472A5 (OSRAM)
JP2009544651A5 (OSRAM)
JP2011037885A5 (OSRAM)
JP2009504909A5 (OSRAM)
JP2007045756A5 (OSRAM)
JP2016502452A5 (OSRAM)